Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 61 results for diabetic foot

  1. What is the most clinically and cost-effective tool for diagnosing peripheral arterial disease in people with diabetes?

    higher risk of cardiovascular events and foot problems such as diabetic neuropathy (nerve damage or degeneration),...

  2. Diabetic foot problems: Inpatient management of diabetic foot problems (CG119)

    This guidance has been updated and replaced by NICE guideline NG19.

  3. Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral neuropathy.

    research is needed on the benefits and consequences of detecting preclinical diabetic peripheral neuropathy. Any explanatory notes(if...

  4. Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (IPG727)

    Evidence-based recommendations on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). This involves replacing damaged cartilage with an artificial (synthetic) implant.

  5. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

  6. 3C Patch for treating diabetic foot ulcers (MTG66)

    We have moved Medical technologies guidance 66 to become HealthTech guidance 615. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  7. 3C Patch System for treating diabetic foot ulcers (MIB230)

    This advice has been updated and replaced by NICE Healthtech guidance 615.

  8. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  9. UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

    We have moved Medical technologies guidance 42 to become HealthTech guidance 502. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  10. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

  11. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

  12. Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)

    This guidance has been updated and replaced by NICE guideline NG19.

  13. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  14. Physiological impacts

    In the Labonte model, physiological impacts refer to the direct effects on the body’s systems and functions due to factors such as stress, lifestyle choices, and environmental conditions.

  15. Diabetes

    Diabetes is one of the key clinical areas of health inequalities identified in NHS England’s Core20PLUS5 framework for children and young people.